TEMPUS AI, INC. CLASS A COMMON STOCK

NASDAQ: TEM (Tempus AI, Inc.)

最近更新时间: 26 Nov, 2:45PM

77.06

0.22 (0.28%)

前收盘价格 76.84
收盘价格 77.84
成交量 3,036,038
平均成交量 (3个月) 7,560,893
市值 13,709,249,536
价格/销量 (P/S) 12.04
股市价格/股市净资产 (P/B) 26.24
52周波幅
31.36 (-59%) — 104.32 (35%)
利润日期 4 Nov 2025
营业毛利率 -88.27%
营业利益率 (TTM) -26.93%
稀释每股收益 (EPS TTM) -5.16
季度收入增长率 (YOY) 75.40%
总债务/股东权益 (D/E MRQ) 262.96%
流动比率 (MRQ) 1.71
营业现金流 (OCF TTM) -193.29 M
杠杆自由现金流 (LFCF TTM) 54.30 M
资产报酬率 (ROA TTM) -43.89%

市场趋势

短期 中期
行业 Health Information Services (US) 看跌 混合的
Health Information Services (全球的) 看跌 混合的
股票 Tempus AI, Inc. 看涨 看涨

AIStockmoo 评分

0.5
分析师共识 4.0
内部交易活动 -3.0
价格波动 2.0
技术平均移动指标 1.5
技术振荡指标 -2.0
平均 0.50

相关股票

股票 市值 DY P/E(TTM) P/B
TEM 14 B - - 26.24
GEHC 39 B 0.16% 17.69 3.66
HQY 8 B - 43.35 4.21
WAY 7 B - 54.32 2.09
BTSG 7 B - 65.85 3.55
RCM 6 B - - 2.14

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

部门 Healthcare
行业 Health Information Services
投资方式 Mid Growth
内部持股比例 43.27%
机构持股比例 38.33%
52周波幅
31.36 (-59%) — 104.32 (35%)
目标价格波幅
80.00 (3%) — 105.00 (36%)
105.00 (BTIG, 36.26%) 购买
95.00 (23.28%)
80.00 (Piper Sandler, 3.82%) 保留
平均值 92.71 (20.31%)
总计 6 购买, 1 保留
平均价格@调整类型 76.70
公司 日期 目标价格 调整类型 价格@调整类型
Morgan Stanley 02 Dec 2025 85.00 (10.31%) 购买 73.97
11 Nov 2025 80.00 (3.82%) 购买 71.56
BTIG 25 Nov 2025 105.00 (36.26%) 购买 76.84
05 Nov 2025 96.00 (24.58%) 购买 82.26
Piper Sandler 11 Nov 2025 80.00 (3.82%) 保留 71.56
22 Oct 2025 105.00 (36.26%) 保留 85.27
HC Wainwright & Co. 07 Nov 2025 89.00 (15.50%) 购买 71.56
12 Sep 2025 98.00 (27.18%) 购买 86.38
Canaccord Genuity 05 Nov 2025 95.00 (23.28%) 购买 82.26
20 Oct 2025 110.00 (42.75%) 购买 92.45
Needham 05 Nov 2025 100.00 (29.77%) 购买 82.26
Guggenheim 26 Sep 2025 95.00 (23.28%) 购买 78.48
显示更多
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
FUKUSHIMA RYAN 76.84 76.84 -223,220 -17,152,225
LEFKOFSKY ERIC P - 76.06 -166,250 -12,644,975
POLOVIN ANDREW - 76.06 -12,874 -979,196
累积净数量 -402,344
累积净值 ($) -30,776,396
累积平均购买 ($) 76.84
累积平均卖出 ($) 76.45
名称 持有人 日期 类型 数量 价格 价值 ($)
FUKUSHIMA RYAN 职员 25 Nov 2025 处理 (-) 125,135 76.84 9,615,373
FUKUSHIMA RYAN 职员 25 Nov 2025 获得 (+) 33,808 76.84 2,597,807
FUKUSHIMA RYAN 职员 25 Nov 2025 处理 (-) 131,893 76.84 10,134,658
POLOVIN ANDREW 职员 24 Nov 2025 自动卖出 (-) 12,874 76.06 979,196
LEFKOFSKY ERIC P 职员 24 Nov 2025 自动卖出 (-) 166,250 76.06 12,644,975
日期 类型 细节
18 Nov 2025 公告 Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
14 Nov 2025 公告 Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
05 Nov 2025 公告 Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
04 Nov 2025 公告 Tempus Reports Third Quarter 2025 Results
28 Oct 2025 公告 Tempus to Participate in the Stifel 2025 Healthcare Conference
21 Oct 2025 公告 Tempus to Report Third Quarter 2025 Financial Results on November 4
20 Oct 2025 公告 Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity
16 Oct 2025 公告 Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
15 Oct 2025 公告 Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
09 Oct 2025 公告 Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
01 Oct 2025 公告 Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
22 Sep 2025 公告 Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
15 Sep 2025 公告 Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
11 Sep 2025 公告 Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
09 Sep 2025 公告 Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票